» Articles » PMID: 10871853

Rac1 in Human Breast Cancer: Overexpression, Mutation Analysis, and Characterization of a New Isoform, Rac1b

Overview
Journal Oncogene
Date 2000 Jun 29
PMID 10871853
Citations 194
Authors
Affiliations
Soon will be listed here.
Abstract

Rac1 is a member of the Ras superfamily of small guanosine triphosphatases (GTPases) that act as molecular switches to control cytoskeletal rearrangements and cell growth. Analogous to Ras, constitutively activating point mutations of Rac1 cause tumorigenic transformation of cell lines. However, there is no information about whether Rac1 is also mutated in vivo. After RT - PCR of Rac1, several clones of seven benign and 10 malignant breast cancer tissues as well as eight breast cancer cell lines were sequenced. Only single-nucleotide polymorphisms of Rac1 could be detected, and none of these corresponded to constitutively activating point mutations that have been used in cell lines for transformation. While sequencing Rac1 in breast tissues, a new Rac1 isoform with an insertion of 19 codons within the reading frame of Rac1 close to switch region II was identified and named Rac1b. The Rac1b protein acts like a fast cycling GTPase in GTP binding and hydrolysis assays. In Northern and Western blot experiments both Rac1 RNA and Rac1 protein had a significantly higher expression in breast cancer tissues compared to normal breast tissue samples. Immunohistochemical staining of Rac1 showed weak Rac1 expression in benign breast disease but high expression level in ductal carcinoma-in-situ, primary breast cancer, and lymph node metastases. In addition, breast tumor cells from patients with recurrent disease had Rac1 expression at the plasma membrane, suggesting activation of Rac1, in patients with aggressive breast cancer. Oncogene (2000).

Citing Articles

Partial Inhibition of Epithelial-to-Mesenchymal Transition (EMT) Phenotypes by Placenta-Derived DBMSCs in Human Breast Cancer Cell Lines, In Vitro.

Basmaeil Y, Subayyil A, Kulayb H, Kondkar A, Alrodayyan M, Khatlani T Cells. 2025; 13(24.

PMID: 39768220 PMC: 11674051. DOI: 10.3390/cells13242131.


Effects of Na1.5 and Rac1 on the Epithelial-Mesenchymal Transition in Breast Cancer.

Zha Z, Ge F, Li N, Zhang S, Wang C, Gong F Cell Biochem Biophys. 2024; .

PMID: 39673684 DOI: 10.1007/s12013-024-01625-x.


Novel inhibitor against Rac1 for therapeutic approach in prevention of breast cancer progression.

Singh A, Koley T, Vats D, Singh A, Samath E, Batra A Sci Rep. 2024; 14(1):25083.

PMID: 39443601 PMC: 11500341. DOI: 10.1038/s41598-024-75351-y.


Next-Cell Hypothesis: Mechanism of Obesity-Associated Carcinogenesis.

Engin A, Engin A Adv Exp Med Biol. 2024; 1460:727-766.

PMID: 39287871 DOI: 10.1007/978-3-031-63657-8_25.


The Roles of RAC1 and RAC1B in Colorectal Cancer and Their Potential Contribution to Cetuximab Resistance.

Wahoski C, Singh B Cancers (Basel). 2024; 16(13).

PMID: 39001533 PMC: 11240352. DOI: 10.3390/cancers16132472.